

# ENTIS OTIS

## JOINT MEETING

2024

Nyborg, Denmark, September 12th-15th



DANSK SØSKAB FOR KLINISK FARMAKOLOGI

Department of  
Clinical Pharmacology  
OUH  
Odense University Hospital  
Svendborg Hospital



# Contents

3 Welcome



4 Venue Information



5 Conference Navigation



6 Welcome Reception & Conference Dinner



8 Social & Leisure Activities



9 Program



13 Session Chairs



14 Speakers



24 Oral Communications & Posters



33 Denmark FAQ



35 Nyborg & Odense



37 Organizers, collaborators & contributors





## THE GREAT BELT BRIDGE

# Welcome

We are happy to welcome you to Nyborg for this year's joint conference of the European Network of Teratology Information Services (ENTIS) and the Organization of Teratology Information Specialists (OTIS). Nestled on the beautiful island of Funen, Nyborg is a city rich in history and charm, offering a great setting for our meeting. On the following pages you will (hopefully) find all information need to support ensure a great meeting and an altogether great and productive experience in the company of friends and collaborators.

We encourage you to explore the city of Nyborg and the vibrant city of Odense, the birthplace of Hans Christian Andersen. Funen, known as the "Garden of Denmark," offers scenic landscapes, cultural treasures, and warm hospitality. See pages 31-34 for details and suggestions.

Cheers,

**Per Damkier, your host, friend and collaborator**

**&**

**The local organizing committee; Daniel P. Henriksen, Kathrine B. Moriat, Erika B. Gram, Lærke K. Overgaard, Katrine B. Johansen, Maria C. Andersen & Anne T. Petersen**

Department of Clinical Pharmacology, Odense University Hospital  
Department of Clinical Research, University of Southern Denmark

# Venue Information


SINATUR HOTEL  
& CONFERENCE



Located in the small, old coastal town of Nyborg, Sinatur Hotel and Conference offers a perfect blend of natural beauty and modern amenities, making it an ideal venue for our conference.


The address of Sinatur Hotel & Conference is Østerøvej 121, 5800 Nyborg, and the hotel is located approximately 1,6 km from Nyborg's train station.

# Conference Navigation



## GROUND FLOOR

The Reception-desk will be located in “Udsigt 2” and the main room for speaker sessions & oral communications is “Flintholm/Sandholm”.



## FIRST FLOOR

The meetings during thursday will take place in the rooms on the first floor, specified in the program. Poster sessions and coffee breaks will also take place on this floor. The welcome reception will take place at the first floor terrace, if the weather allows it.

# Welcome Reception

The opening reception of the ENTIS OTIS joint meeting will take place on thursday september 12th 19.30 until approximately 21.00, at the first floor terrace of the conference venue.

The reception will include a light refreshment.

VIEW FROM THE  
SINATUR TERRACE



# Conference Dinner

The Restaurant is situated in an old rebuilt train repair hall (“Remise”). We will occupy an adjacent building by ourselves. It is about 1.5 kilometer (1 mile) from the venue. There will be a shuttle bus from the Venue from 1830-1900 and back to the venue between 2300 and 0215.


Adjacent to the Restaurant, the local renowned distillery ([www.nyborgdestilleri.com](http://www.nyborgdestilleri.com)), that specializes in mainly gin and whisky, has a store, if you want a local souvenir



# Social & Leisure Activities



## Guided leisure run



*Time: Friday the 13th of September at 07.00-08.00 (Run starts precisely at 07.05)*

*Guide: Troels K. Bergmann*

*Starting point: Lobby of conference venue (Sinatur Hotel)*

*Route: marked in green, on the map. 6.8 km.*

Please join Troels for a leisurely morning run, paced so that everybody is comfortable. No warm up is needed. There is no signing up, just show up, at above starting point, in your running outfit.

## Morning swim

For those who would like to uphold or join our relatively new and informal tradition of open-water swimming, this meeting is just the right opportunity to dive in!

The venue is situated—quite literally—on one of the finest beaches in Denmark; 50 meters and you are in the waves!

We meet at 07.00 every morning.

# Program

TIME	EVENT	ROOM
<b>THURSDAY 12TH SEPTEMBER 2024</b>		
08.00-19.00	Registration desk open	
08.00-17.00	Board & Committee Meetings (OTIS & ENTIS separately)	
08.00-17.00	OTIS Meetings	Egholm
10.00-11.30	ENTIS: Board Meeting	Musholm
11.30-12.00	ENTIS: Website Meeting	Musholm
12.00-12.30	ENTIS: concePTION Commitee Meeting	Musholm
12.30-13.30	Lunch	
13.30-14.30	ENTIS: Scientific Committee Meeting	Musholm
14.30-15.00	Joint OTIS & ENTIS Research Committee Meeting	Musholm
15.00-15.30	Coffee	
15.30-17.30	ENTIS Business Meeting	Musholm + Helleholm
19.30-21.00	Official meeting opening & welcome reception	First floor

# Program

FRIDAY 13TH SEPTEMBER 2024	
TIME	EVENT
VACCINATION IN PREGNANCY: LESSONS FROM COVID-19	
09.00-09.45	Viki Male (UK) - Vaccines in pregnancy and scientific misinformation
09.50-10.20	Coffee
VACCINATION IN PREGNANCY: LESSONS FROM COVID-19 CONTINUED	
10.25-10.45	Nina Palesa Bonde (DK) - A patient perspective
10.50-11.20	Annemette Lykkesbo (DK) - A clinical perspective
11.25-11.55	Ulla Wändel Liminga (SE) - A regulatory perspective
11.55-12.15	Panel discussion
12.15-13.15	Lunch
13.15-13.45	Poster session
MULTINATIONAL REGISTRY STUDIES ON DRUGS IN PREGNANCY: CHALLENGES AND PERSPECTIVES	
13.45-14.30	Krista Huybrechts (US) - Multinational registry studies on drugs in pregnancy: challenges and perspectives
14.30-14.45	Panel discussion
ORAL COMMUNICATIONS	
14.50-15.01	Lukas Lohse (DE) - Methodological lessons from the Embryotox cohort study on COVID-19 vaccine safety during pregnancy
15.05-15.16	Anick Berard (CA) - Characterizing medication use patterns among pregnant and non-pregnant patients with COVID-19 in the Canadian Mother-Child Cohort (CAMCCO)
15.20-15.45	Coffee & Poster session
TREATMENT OF PAIN IN PREGNANCY	
15.50-16.25	Lars Henning Petersen (DK) - Clinical approach & controversies
16.30-16.55	Sura Alwan (CA) & Per Damkier (DK) - Acetaminophen in pregnancy & childhood ASD/ADHD: Current state of affairs
17.00-17.25	Panel discussion

# Program

SATURDAY 14TH SEPTEMBER 2024	
Time	Event
ONGOING PROJECTS AND PRINCIPLES FOR DEVELOPMENT OF GUIDANCE DOCUMENTS	
09.00-09.30	Lorrie Harris-Sagaribay (US) & Kirstie Perrotta (US) - Update: CDC Grant to Enhance Partnerships
09.35-10.05	Benedikte-Noël Cuppers (NL) & Fergal O'Shaughnessy (IRE) - The ConcePTION project: Update and lessons learned
10.05-10.30	Coffee
ONGOING PROJECTS AND PRINCIPLES FOR DEVELOPMENT OF GUIDANCE DOCUMENTS CONTINUED	
10.35-12.15	Workshop Chris Stallman (US) & Luke Richardson (UK) - Comparing development of public exposure documents.
12.15-13.15	Lunch
13.15-13.35	Walk, Talk & Networking
13.40-14.40	Poster Session
14.40-15.05	Coffee
ORAL COMMUNICATIONS	
15.10-15.21	Michael Ceulemans (Presented by Marleen van Gelder) (BE) Periconceptional oral contraceptive use and the risk of miscarriage: results from the PRIDE study
15.25-15.36	Marleen Van Gelder (NL) Association of non-steroidal anti-inflammatory drug use during pregnancy and miscarriage: a Norwegian registry linkage study
15.40-15.51	Ursula Winterfeld (CH) Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services
15.55-16.06	Matthew Bluett-Duncan (UK) Developing a caregiver reported questionnaire set for neurodevelopmental outcomes in school-aged children for pregnancy pharmacovigilance surveillance: a contribution from the ConcePTION project
QUIZ SHOW	
16.10-17.00	Orna Diav-Citrin (IL) & Svetlana Schectman (IL) - Drugs in pregnancy: Test yourself on recent papers.
19.00	Conference Dinner

# Program

## SUNDAY 15TH SEPTEMBER 2024

Time	Event
HOT TOPICS	
09.00-09.40	Leyla Sahin (US) & Hedvig Nordeng (NO) - Drugs in Pregnancy and Lactation regulatory labelling - status and perspectives from FDA and EMA
09.40-09.55	Panel discussion on labelling in pregnancy & lactation
10.00-10.35	Sam Lockhart (UK) - New insights on role of GDF15 in NPV & hyperemesis gravidarum
10.40-11.00	Coffee
11.05-11.35	Éva Mikó (HU) - The Maternal-Fetal microbiome
ORAL COMMUNICATIONS	
11.45-11.56	Delwyn Cupitt (AU) - Implementation of a Hyperemesis Gravidarum phone advice service for medications advice
12.00-12.11	Laure Sillis (BE) - Medications for nausea and vomiting of pregnancy: a prospective cohort study assessing the risk for preterm birth, small for gestational age and neonatal intensive care unit admissions
12.15-12.26	Martje Van Neste (NL) - Clopidogrel exposure in human milk The UmbrellACT study - A contribution from the ConcePTION project
12.30-12.41	Essi Whaites Heinonen (SE) - Composition of macronutrients in human milk during maternal anti-inflammatory drug treatment
12.45	Lunch
14.00	Farewell, Meeting end

# Session Chairs

## SESSION 1 - VACCINATION IN PREGNANCY: LESSONS FROM COVID-19

Brian Cleary, Rotunda Hospital, Dublin, Ireland

Per Damkier, Odense University Hospital, Odense, Denmark

## SESSION 2 - MULTINATIONAL REGISTRY STUDIES ON DRUGS IN PREGNANCY: CHALLENGES AND PERSPECTIVES & ORAL COMMUNICATIONS

Benoît Marin, Sorbonne University, Paris, France

Hedvig Nordeng, University of Oslo, Norway

## SESSION 3 - TREATMENT OF PAIN IN PREGNANCY

Ken Hodson, University of Newcastle, UK

Sarah Obican, University of South Florida, USA

## SESSION 4 - ONGOING PROJECTS AND PRINCIPLES FOR DEVELOPMENT OF GUIDANCE DOCUMENTS

Al Romeo, MotherToBaby, Utah, USA

Maya Berlin, Ministry of Health, Israel

## SESSION 5 - ORAL COMMUNICATIONS (SATURDAY)

Sura Alwan, University of British Columbia, Canada

Laure Sillis, KU Leuven, Belgium

## SESSION 7 - HOT TOPICS

Stephanie Padberg, Charité Universitätsmedizin Berlin, Germany

Debra Kennedy, University of New South Wales, Australia

## SESSION 8 - ORAL COMMUNICATIONS (SUNDAY)

Anneke Passier, Lareb, The Netherlands

Matthew Bluett-Duncan, University of Manchester, UK

# Speakers

## VIKI MALE (UK)

Senior Lecturer in Reproductive Immunology  
Imperial College London



---

In December 2020, as the COVID vaccine rollout began, rumours started to circulate that antibodies raised by vaccination would target a placental protein, Syncytin-1, causing infertility and miscarriages. My work is on how the maternal immune system interacts with placental cells, so I felt a responsibility to explain why there was no basis to this rumour, and the evidence that COVID vaccination doesn't impact female fertility. As I became more involved in this work, people naturally started to ask about the evidence that COVID vaccination is safe and effective in pregnancy, so I collated and communicated the evidence on this. In this talk, I will reflect on what our experiences during the pandemic can teach us about public communication on the safety of medicines in pregnancy.

## NINA PALESA BONDE (DK)

Copenhagen, Denmark



---

Nina was pregnant during the COVID-19 pandemic in Denmark in spring/early summer of 2021. At this point, the new vaccines were not approved for, or available to, pregnant women in Denmark. This caused concerns, uncertainty and frustrations, and she will share some thoughts from the perspective of a pregnant woman

# Speakers

## ANNEMETTE W. LYKKEBO (DK)

MD, Head of Department,  
Department of Gynecology &  
Obstetrics  
Odense University Hospital



---

I hold a specialist authorization in gynecology and obstetrics and has had a long clinically oriented career. I have led 2 large gynecology and obstetrics departments in Denmark.

During the COVID-19 pandemic, I was president of the Danish Society of Obstetrics and Gynecology (DSOG).

I was part of a clinical taskforce that made guidelines regarding how to prevent COVID-19 and treat pregnant and birth-giving women affected by COVID. The taskforce served as advisory board for the National board of Health. When the vaccines were introduced, the group was expanded and we worked intensively to ensure that the vaccine was offered to pregnant women.

## ULLA WÄNDEL LIMINGA (SE)

Dr of medical sciences, pharmacist  
Scientific Director Pharmacovigilance  
Swedish Medical Products agency



---

Dr Ulla Wändel Liminga has been working at the Swedish Medical Products Agency and within the EU regulatory system for approximately 30 years. She is an assessor of non-clinical pharmacology and toxicology, clinical efficacy, and particularly clinical safety and pharmacovigilance. She has been the Scientific Director Pharmacology and Toxicology 2008-2020, Scientific Director Pharmacovigilance from 2020 and one of the Swedish PRAC members since 2012. She has a special interest in risk assessment and recommendations regarding the use of medicines during pregnancy. She has been involved in drafting regulatory guidelines within this area, as well as in other areas within non-clinical pharmacology, toxicology and pharmacovigilance.

# Speakers

## KRISTA HUYBRECHTS (US)

MS, PhD  
Associate Professor of Medicine  
and Epidemiology  
Brigham and Women's Hospital, Harvard Medical  
School




---

Dr. Huybrechts co-founded and co-directs the Harvard Program on Perinatal and Pediatric Pharmacoepidemiology. Her research centers on generating evidence regarding the safety and effectiveness of prescription medications during pregnancy. Her work, which is funded primarily by the National Institutes of Health, focuses on the use of advanced epidemiological and statistical methods applied mainly to large databases derived from health data collected in the context of routine medical care to help address the unique questions regarding benefit-risk trade-off for prescription medication use faced by women of reproductive age and pregnant women. Dr. Huybrechts is a member of the Editorial Board of JAMA Psychiatry and an Associate Editor for Pharmacoepidemiology and Drug Safety. She served on the Board of Directors of the International Society of Pharmacoepidemiology (ISPE) as Vice President Finance from 2017-2020. She currently serves on the board of Marcé of North America (MONA, Perinatal Mental Health Society) and is a voting member for the FDA Drug Safety and Risk Management Advisory Committee.

## LARS HENNING PETERSEN (DK)

Professor, senior consultant, PhD  
Dept. Obstetrics and Gynecology, Aarhus  
University Hospital & Dept. Clinical  
Medicine, Aarhus University



---

Obstetrician, subspecialised in maternal-fetal medicine. PhD in reproductive epidemiology. Epidemiological and clinical studies on medication in pregnancy based on international, multidisciplinary collaborations.

# Speakers

## SURA ALWAN (CA)



Co-Director, TERIS (The Teratogen Information System), and Shepard's Catalog of Teratogenic Agents, UW  
Clinical Instructor, UBC

---

A PhD geneticist and a trained birth defects epidemiologist and teratologist interested in identifying exposures in pregnancy (specifically with regard to chronic diseases and associated medications) that may pose a risk to the developing fetus and contribute to causing birth defects and neurodevelopmental outcomes.

Background education: Bachelor of Science in Human Genetics from the University of Nottingham, Masters of Science in Medical Genetics from the University of Glasgow, Doctorate degree in Medical Genetics (Risk assessment of birth defects) from the University of British Columbia.

## PER DAMKIER (DK)



Professor, MD, PhD  
Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark  
Department of Clinical Research, University of Southern Denmark, Odense, Denmark

---

The use of drugs in pregnancy, both with respect to drug utilization and the risk of unwanted fetal effects, has been a main area of interest and research for about 20 years. I emphasize clinical utilization of research and communication of results to non-academic communities. I write all texts on pregnancy and lactation in the Danish decision support system [www.pro.medicin.dk](http://www.pro.medicin.dk) (equivalent to the Physicians' Desk Reference).

I'd like to believe 😊 that I am a fairly well-known (for better and worse) author of scientific letters, commentaries, and editorials on the use of acetaminophen in pregnancy and childhood neurodevelopmental issues, especially ASD and ADHD.

# Speakers

## LORRIE HARRIS-SAGARIBAY (US)

Teratogen Information Specialist and Program Coordinator, MotherToBaby North Carolina



---

Lorrie Harris-Sagaribay, MPH, is a teratogen information specialist with MotherToBaby North Carolina, where she provides exposure risk counseling in English and Spanish to healthcare providers and the general public. She also conducts outreach and professional education, including guest lectures on teratology in the genetic counseling graduate program at the University of North Carolina at Greensboro. As co-chair of the MotherToBaby Emerging Issues Task Force, Lorrie helped guide OTIS/MotherToBaby in a collaborative public health response to Zika and COVID-19 with the Centers for Disease Control and Prevention (CDC). She currently serves as a Senior Project Leader for a 5-year cooperative agreement awarded to OTIS by CDC, which focuses on building partnerships to improve health outcomes for pregnant and postpartum people and their infants. After serving with the United States Peace Corps in Honduras, Lorrie earned her Masters of Public Health from the University of North Carolina at Chapel Hill with a concentration in maternal and child health. Lorrie currently serves on the OTIS Board of Directors as President-Elect.

## KIRSTIE PERROTTA (US)

Teratogen Information Specialist, MotherToBaby California, University of California, San Diego (UCSD)



---

Kirstie Perrotta, MPH, is a Teratogen information specialist with MotherToBaby California where she answers questions about various exposures during pregnancy and lactation via phone, live chat, and email. As co-chair of the Emerging Issues Task Force (EITF), Kirstie played a key role in MotherToBaby's emergency response efforts to Zika and COVID-19. Kirstie currently serves as a Senior Project Leader for a 5-year cooperative agreement awarded to the Organization of Teratology Information Specialists (OTIS) by the Centers for Disease Control and Prevention (CDC), which focuses on building partnerships to improve health outcomes for pregnant and postpartum people and their infants. She holds the position of Affiliate Liaison on the OTIS Board of Directors and is a Steering Committee Member with the San Diego Immunization Coalition (SDIC). Kirstie received her Masters of Public Health (MPH) from the University of San Francisco (USF).

# Speakers

## BENEDIKTE- NÖEL CUPPERS (NL)



Pharmacist and scientific associate/  
teratology information specialist  
Teratology Information Service  
Pharmacovigilance center Lareb,  
Netherlands

---

After working in community pharmacy as a pharmacist for 10 years, I switched to TIS Netherlands in 2003. I have been working there with great pleasure for 21 years. Much of my time is spent running phone shifts for healthcare providers and the public, keeping up with the literature and incorporating it into our knowledge pages, writing articles and giving lectures to students.

In 2020, I joined the Conception project. I contributed to the development and content (knowledge pages) of Mums and the Learning for healthcare professionals.

## FERGAL O'SHAUGHNESSY (IRE)



Senior Pharmacist, Irish Medicines in  
Pregnancy Service (IMPS), Rotunda Hospital,  
Dublin, Ireland  
·Honorary Clinical Senior Lecturer, School of  
Pharmacy and Biomolecular Sciences, Royal  
College of Surgeons in Ireland (RCSI)

---

Senior pharmacist working to establish the Irish Medicines in Pregnancy Service at the Rotunda Hospital, supporting safe and effective medication use in pregnant and breastfeeding women through information and counselling, advocacy, research and education.

Participation as a linked third party of ENTIS to the ConcePTION project.  
Contribution to WP5 and the development of the e-learning package and MUMS Knowledge bank.

# Speakers

## CHRIS STALLMAN (US)

MLS, MS, CGC  
Director, MotherToBaby Arizona  
& director of University of  
Arizona genetic counseling  
graduate program



---

Chris is associated with OTIS, MotherToBaby as well as the Society for Birth Defects Research and Prevention. She works in health literacy, education and teratology.

## LUKE RICHARDSON (UK)

Dr (PhD), Principal Medical Information  
Scientist and Data Manager  
UK Teratology Information Service,  
Newcastle upon Tyne Hospitals NHS  
Foundation Trust



---

Luke has worked at the UK Teratology Information Service (UKTIS) since 2009. His main research interests include improving UK teratogen surveillance techniques, international collaborative approaches for pregnancy drug safety studies, and developing academic standards in data collection, data synthesis and risk communication for pregnancy drug safety. Luke also helps to maintain the UKTIS medication safety online literature, which includes electronic information pages for healthcare providers and pregnant women. He is currently working on an international project (IMI ConcePTION) aiming to improve approaches to studying drug safety in pregnancy and risk-benefit communication to women and healthcare providers.

# Speakers

## ORNA DIAV-CITRIN (IL)

MD, Senior physician in charge of the Israeli Teratology Information Service



---

Orna Diav-Citrin is an Adjunct Clinical Associate Professor in Teratology at the Hebrew University-Hadassah School of Medicine, Jerusalem, Israel. She earned her MD from the Hebrew University, completed her residency in Pediatrics at Bikur Cholim General Hospital, Jerusalem, and spent three years as a Post-Doctoral Fellow in Clinical Pharmacology and Toxicology at the University of Toronto, Motherisk Program, Hospital for Sick Children, Canada. She is a senior physician and in charge of the Israeli Teratology Information Service, Ministry of Health. She combines clinical work, teaching, and research in Clinical Teratology. Her main research interest is the safety versus risk of environmental exposures in pregnancy, including medications, infectious agents, and maternal diseases. She is a member of OTIS, BDRP, ENTIS and ETS. She has joined the ENTIS board in 2018 and serves as the President of ENTIS since 2019.

## SVETLANA SCHECTMAN (IL)

Senior Teratology Consultant, Israeli Teratology Information Service, Jerusalem



---

Dr. Scheckman received her PhD from the Hebrew University, Jerusalem, Israel. She is a teratology information service counselor since 1998. The main research field is Clinical Teratology. She was an ENTIS board member for several years and now is a member of ENTIS scientific committee. She is co-author of many studies in the field of drugs and other exposures safety in pregnancy, including several ENTIS multi centered studies.

# Speakers

## LEYLA SAHIN (US)

MD, Deputy Director for Safety, Division of Pediatrics and Maternal Health  
US Food and Drug Administration (FDA)  
Center for Drug Evaluation and Research (CDER)



---

Leyla Sahin, MD is an obstetrician-gynecologist who serves as the Deputy Director for Safety in the Division of Pediatrics and Maternal Health in the Office of New Drugs, Center for Drug Evaluation and Research at FDA. She oversees pregnancy and lactation safety activities and leads various maternal health related scientific and regulatory/policy initiatives. She joined FDA in 2008 as a medical officer after practicing obstetrics and gynecology for twelve years.

## HEDVIG NORDENG (NO)

Professor, Department of Pharmacy, University of Oslo (UiO).



---

Professor Nordeng's research experience and expertise lies within perinatal pharmacoepidemiology and pharmacotherapy during pregnancy and breast feeding. She has a long track record of interdisciplinary research and of international research projects, using large population-based cohorts and linked health care registries, especially in the Nordic countries. She was awarded an ERC Grant for the project "DrugsInPregnancy". Prof. Nordeng is the editor of a textbook in clinical pharmacology for nurses and has authored over 200 scientific articles, book chapters and clinical guidelines, many of which focus on perinatal drug use and safety. As of 2018, she has been an EU commission appointed independent scientific expert member of PRAC, European Medicines Agency. She is a member of NorPEN (Nordic Pharmacoepidemiology Network) and a fellow of the International Society of Pharmacoepidemiology (FISPE). As of 2024, she holds an affiliation as adjunct Professor position in Clinical Pharmacology at the Faculty of Health Sciences, University of Southern Denmark.

Read more about her research here:

[www.mn.uio.no/farmasi/english/research/groups/pharma-safe/index.html](http://www.mn.uio.no/farmasi/english/research/groups/pharma-safe/index.html)

# Speakers

## SAM LOCKHART (UK)

Academic Clinical Lecturer, Specialist Registrar in Diabetes and Endocrinology, Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, UK. Institute of Metabolic Science, University of Cambridge, UK.



---

Sam is a clinician-scientist who uses human genetics to prioritize hypotheses regarding the mechanisms of human cardiometabolic and endocrine-related diseases. Working as part of a large, international multi-disciplinary team led by Professor Sir Stephen O'Rahilly, Sam and colleagues conducted studies in cells, mice and humans to determine that genetic pre-disposition to severe pregnancy sickness is driven by the sensitivity to GDF15, a placental-derived emetic hormone that rises markedly in pregnancy. This work provides a mechanistic basis for the pathophysiology of pregnancy sickness with implications for treatment and prevention.

## ÉVA MIKÓ (HU)


MD, PhD, associate professor  
University of Pecs



---

Dr. Mikó is a specialist for medical microbiology and molecular genetic diagnostics and describes her research as follows. As an immunologist and microbiologist, my research focuses on reproductive immunology, particularly concerning female reproductive challenges such as idiopathic infertility with repeated implantation failures during in vitro fertilization (IVF) procedures and habitual abortion. I am particularly interested in investigating maternal immunotolerance mechanisms on both local (decidual) and systemic (peripheral blood) levels. Additionally, I am exploring the role of the microbiota residing in the reproductive tract in achieving successful reproduction. Currently, I have ongoing research projects examining the impact of endometrial microbiota on reproductive success and the establishment of fetal/newborn microbiota.

# Oral Communications



LUKAS  
LOHSE (DE)

---

Methodological lessons from the  
Embryotox cohort study on COVID-  
19 vaccine safety during pregnancy

ANICK  
BERARD (CA)

---


Characterizing medication use  
patterns among pregnant and non-  
pregnant patients with COVID-19 in  
the Canadian Mother-Child Cohort  
(CAMCCO)



MICHAEL  
CEULEMANS (BE)

---

Periconceptional oral contraceptive  
use and the risk of miscarriage: results  
from the PRIDE study (presented by  
Marleen van Gelder, NL)



# Oral Communications



MARLEEN  
VAN GELDER (NL)


---

Association of non-steroidal anti-inflammatory drug use during pregnancy and miscarriage: a Norwegian registry linkage study

URSULA  
WINTERFELD (CH)

---

Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services



MATTHEW  
BLUETT-DUNCAN (UK)

---

Developing a caregiver reported questionnaire set for neurodevelopmental outcomes in school-aged children for pregnancy pharmacovigilance surveillance: a contribution from the ConcePTION project



# Oral Communications



PENELOPE  
FOTHERNGHAM (AU)

---

Implementation of a Hyperemesis  
Gravidarum phone advice service for  
medications advice (presented by  
Delwyn Cupitt).

LAURE  
SILLIS (BE)

---


Medications for nausea and vomiting  
of pregnancy: a prospective cohort  
study assessing the risk for preterm  
birth, small for gestational age and  
neonatal intensive care unit  
admissions



MARTJE  
VAN NESTE (NL)

---

Clopidogrel exposure in human milk  
The UmbreLACT study- A  
contribution from the ConcePTION  
project



# Oral Communications

ESSI  
WHAITES HEINONEN (SE)

---

Composition of macronutrients in  
human milk during maternal anti-  
inflammatory drug treatment.



# Posters

FRIDAY

- 1 **MAARTJE CONIJN**  
Breastfeeding related adverse drug reactions of triptans
- 2 **MATTEO MAGGI**  
Multi-drug treatment of migraine during pregnancy: a complex case
- 3 **SARAH MONDADA**  
Pregabalin Safety in Pregnancy: A Disproportionality Analysis of the Vigibase Spontaneous Reporting System
- 4 **CHAGIT KLIEGER, AYELET DANGOT**  
The long-term neurodevelopmental outcomes of 13 children exposed to Lacosamide during pregnancy
- 5 **ESSI WHAITES HEINONEN**  
Lower rate of breastfeeding in mothers treated with chronically used anti-inflammatory medications
- 6 **JOAN DEVIN**  
Trends in Use of Antiseizure Medicines in Women of Childbearing Potential in an Irish Maternity Hospital: A Preliminary Analysis
- 7 **MARIA HOELTZENBEIN**  
Bias from non-responding in observational cohort studies? Characteristics of pregnant women with levetiracetam treatment stratified by follow-up status in the Embryotox cohort
- 8 **MILICA ZUGIC**  
Development and evaluation of the Medication Adherence Measurement in Pregnancy scale for antidepressants
- 9 **EYDIE MOSES-KOLKO**  
Does the literature in the last decade effectively communicate the risk of gestational antidepressant exposure on congenital malformations?
- 10 **TINA BAKKEBØ**  
Use of SSRI during pregnancy – which elements addressing benefit and risk are included in written answers to patients?
- 11 **JOÃO FOLETTO**  
Valproic acid alters the expression of autophagy genes: a transcriptome meta-analysis
- 12 **JUDITH COTTIN**  
Neurodevelopmental disorders after in utero exposure to carbamazepine monotherapy: a systematic review and meta-analysis
- 13 **JUDITH COTTIN**  
Beta-blockers exposure during pregnancy and growth parameters or preterm birth: a systematic review and meta-analysis
- 14 **JUDITH COTTIN**  
Risk of use of calcium channel blockers during pregnancy: systematic review and meta-analysis of observational studies

# Posters

FRIDAY, CONTINUED

15

NAHO YAKUWA

Ensitrelvir Fumaric Acid initiatives for cases of use during pregnancy

16

VERONIQUE MAAS,  
PETRA WOESTENBERG

Differences in self-reported adverse events after the first mRNA COVID-19 vaccination between pregnant and non-pregnant women

17

VERONIQUE MAAS

Levothyroxine dosage is often not increased among pregnant women with hypothyroidism; data from the Dutch Pregnancy Drug Register

18

EMILIE VITTAZ

Neonatal hypothyroidism associated with in utero exposure to pembrolizumab or nivolumab

19

MORGANE SWITAL

Adverse pregnancy outcomes associated with in utero exposure to multiple sclerosis disease-modifying therapies in France: a nationwide cohort study

20

ALISON OLIVER

No increased risk of miscarriage following maternal mebendazole use in pregnancy: a prospective observational cohort study

21

GEORGIOS  
ELEFThERIOU

Gordon's syndrome in pregnancy. A case-report

22

GEORGIOS ELEFThERIOU

Untreated Wilson disease in pregnancy: a case report

23

LAURE SILLIS

Experiences of women participating in the BELpREG pregnancy registry in Belgium: results from a cross-sectional survey

24

LAURE SILLIS

Data consistency between medical records and BELpREG cohort data related to specific maternal and infant outcomes

25

MAUD DE FEIJTER

Predictors for incorrect vitamin D intake among pregnant women in the Netherlands

26

REEM HEGLA-  
MURAD

Pregnancy outcome following first-trimester exposure to bilastine: case-series of 37 pregnancies

27

BENEDIKTE CUPPER

Prospective case series of tiotropium use in pregnancy

28

SOPHIE GAUTIER

Use of CFTR modulators during pregnancy: a French collaborative descriptive study

# Posters

SATURDAY

- 
- 1** **EMILIE ERIKSEN**  
An Analysis of RMPs and Physicians' Perception of Section 4.6 "Fertility, pregnancy and lactation" of the SmPC for EMA-Approved Medications (2017-2019)
  - 2** **ELKANA KOHN**  
Pregnancy and Lactation: A Call for Harmonization Towards Global Prescribing Information
  - 3** **MICHAEL CEULEMANS**  
Information discrepancies between leaflets and specific resources related to the safety of TNF-alpha and interleukin inhibitors during pregnancy and lactation
  - 4** **ANNEKE PASSIER**  
Dose adjustment in pregnancy based on PBPK modeling: project MADAM
  - 5** **DOMONIQUE MASSET**  
The role of living systematic reviews and meta-analyses tool in the regulatory Decision-Making
  - 6** **MIKADO GOTO**  
Post-Marketing Pharmacovigilance Practices for Pregnancy: A Survey of Japanese Pharmaceutical Companies
  - 7** **IDA HEERFORDT**  
Suspected infant drug reactions to drugs transmitted through breast milk
  - 8** **GEORGIOS ELEFThERIOU**  
Consensus Panel Recommendations for the Pharmacological Management of Breastfeeding Women with Postpartum depression
  - 9** **GRO HAVNEN**  
Monoclonal antibodies during breastfeeding - Challenges with Relative Infant Dose (RID)
  - 10** **JENNY SVEDENKRANS**  
Implementation of a clinical guideline for feeding preterm infants breastmilk from mothers treated with antihypertensive medications
  - 11** **JOAN DEVIN**  
Medication use in pregnancy and breastfeeding – Encouraging shared decision-making through information provision, advocacy, and support
  - 12** **MAYA BERLIN**  
Follow-up of women treated with medications during pregnancy: Not Every Digital System is successful
  - 13** **MATITIAHU BERKOVITCH**  
TIS and Beyond - Enhancing Accessibility and Expanding Teratology Information Services (TIS) through Telemedicine
  - 14** **VERONIQUE MAAS**  
A mobile app to inform pregnant and breastfeeding women about the safety of over-the-counter medicines – The MediMama app

# Posters

SATURDAY, CONTINUED

15

ARIANE WAHLISS

Use of embryotox.de in routine healthcare – the pharmacists' perspective

16

JULIA REPONEN

Use of social media to promote medicine safety during pregnancy and breastfeeding

17

MARTJE VAN NESTE

Challenges and opportunities during clinical lactation studies investigating medicines exposure, experiences from the UmbreLACT study – A contribution from the ConcePTION project

18

MARTJE VAN NESTE

Monomethyl fumarate exposure into human milk: the UmbreLACT study – A contribution from the ConcePTION project

19

REBECCA L. BROMLEY

Implementation of neurodevelopmental surveillance as routine in pregnancy pharmacovigilance: The LIFETIME framework, a contribution from the ConcePTION Project

20

URSULA WINTERFELD

Improving data collection in pregnancy safety studies: evaluating the feasibility of standardised data analysis of pregnancy reports from public and private partners, a contribution from the ConcePTION project

21

SARA MIRANDA

Prescription medication use during pregnancy in France between 2010 and 2022: a nationwide study

22

ULRIKA NÖRBY

Trends in use of medicines during early pregnancy in Sweden 1997–2021

23

AYLIN TOPLU

A Case Report: Breast Cancer, Diabetes, and Pregnancy: Management Challenges

24

WOLFGANG PAULUS

Conception under antidiabetic therapy with sitagliptin

25

JONATHAN RICHARDSON

Intravitreal anti-VEGF biologics in pregnancy: case report and review of the literature

26

MINE KADIOGLU DUMAN, TALHA GURSOY

Goserelin in a Pregnant Woman With Breast Cancer

27

MINE KADIOGLU DUMAN, TALHA GURSOY

Ixekizumab use in pregnancy: Case report

28

ZAFER GÖREN

Exposure to palbociclib and letrozole during second trimester pregnancy: A case report from Marmara University Teratogen Information Service

# Posters

SATURDAY, CONTINUED

29

KSENIA  
ZAGORODNIKOVA

Warfarin-PLGA nanoparticles to limit  
transplacental transfer of warfarin

30

KSENIA  
ZAGORODNIKOVA

Paclitaxel-carboplatin associated  
oligohydramnios

# Denmark



CHARMING STREETS  
OF ODENSE

On the following page we have included some essential information, that you might find useful and hopefully make your stay in Denmark even more enjoyable!

## Safety & security

Denmark is consistently ranked as one of the safest countries in the world. Nyborg, like the rest of Denmark, is known for its low crime rates and friendly atmosphere. It's safe to walk around alone, even in the evenings, so feel free to explore the town and enjoy the local culture.

## Emergency Contacts

While we hope you won't need it, it's good to be prepared:

Emergency Number: Dial 112 for police, ambulance, or fire services.

Non-Emergency Police Number: For non-urgent matters, dial 114.

The nearest hospital with emergency services is Odense University Hospital (Klørvænget 25, 5000 Odense C)

## Language

Danish is the official language, but English is widely spoken and understood, especially in larger towns and cities like Nyborg. You'll find that most Danes are fluent in English and eager to assist visitors.



## Transportation

Denmark boasts an efficient public transport system. In Nyborg, you can easily get around by bus, taxi, or bike. The town is pedestrian-friendly, so walking is often the best way to explore. If you're traveling outside Nyborg, the train services are reliable and can take you to major cities like Odense (20 minutes, pictured above) and Copenhagen (1 hour).

## Currency & Payments

The currency in Denmark is the Danish Krone (DKK). Credit cards (especially Visa and MasterCard) are widely accepted. ATMs are readily available throughout Nyborg.

## Climate & Clothing

The weather in Denmark can be unpredictable, even during the summer months. It's wise to pack layers, including a waterproof jacket, and comfortable shoes for walking. Check the weather forecast before you travel to be prepared.

## Electricity

Denmark uses Type E and K sockets with a standard voltage of 230V and a frequency of 50Hz. If you're coming from a country with different plug types, don't forget to bring an adapter.

## Local Etiquette

Danes are known for their politeness and respect for privacy. When greeting someone, a firm handshake is customary. Punctuality is highly valued, so please be on time for all conference sessions and appointments. While tipping is appreciated, it is never required or expected.

## Health & Wellness

Tap water in Denmark is of high quality and safe to drink. Pharmacies are available for any over-the-counter needs.



# Nyborg

Nyborg is a charming coastal town with a rich history and a central location on the island of Funen. As one of Denmark's oldest towns, Nyborg offers a unique blend of historical significance, beautiful scenery, and warm Danish hospitality.

## A Town Steeped in History

Nyborg is home to Nyborg Castle, one of Denmark's most important medieval fortresses. Originally built in the 12th century, the castle played a crucial role in Danish history as the residence of kings and the meeting place for the first Danish parliament. Today, you can visit the castle and explore its fascinating museum, which brings history to life through engaging exhibits and events.

## Scenic Beauty and Outdoor Activities

Surrounded by lush landscapes and the sparkling waters of the Great Belt, Nyborg offers plenty of opportunities for outdoor activities. The town's beaches are perfect for a relaxing day by the sea, while the surrounding forests and parks are ideal for hiking, cycling, or a leisurely stroll. The Nyborg Marina is a hub of activity, where you can watch the boats, enjoy fresh seafood, or take a scenic boat tour.

## A Walkable Town with Easy Access

Nyborg's compact size makes it easy to explore on foot. Take a leisurely walk through the town center, where you'll find a mix of historic buildings, quaint shops, and inviting cafes. The town's location also makes it an excellent base for exploring the rest of Funen, with easy access to nearby attractions by car, train, or bike..

## Dining options

The conference venue has its own restaurant; Restaurant Sinatur, a very nice and largely organic based option. Another choice is the Michelin guide recommended Liefroy, where booking a good while in advance is necessary. Other recommendations in Nyborg includes Restaurant Hesselet, Restaurant Remisen and Den Gode Smag.

# Odense

Welcome to Odense, the charming and vibrant city located in the heart of the island of Funen, just a short journey from Nyborg. As Denmark's third-largest city, Odense offers a perfect blend of rich history, cultural experiences, and modern attractions.

## A City of History and Culture

Odense is perhaps best known as the birthplace of the world-famous fairy tale author Hans Christian Andersen. Explore the life and legacy of Andersen by visiting the Hans Christian Andersen Museum, his childhood home, and various statues and landmarks dedicated to his stories throughout the city. The historic quarter, with its cobblestone streets and colorful houses, offers a glimpse into the past and is perfect for a leisurely stroll.

## Vibrant Attractions

Odense boasts a wide array of attractions for all interests. The Odense Zoo is one of the best in Europe, offering an immersive experience with exotic animals. For those interested in history, the Funen Village (Den Fynske Landsby) is an open-air museum that recreates life in a Danish village from the 19th century. The Brandts Museum of Art and Visual Culture showcases contemporary art, photography, and design, appealing to modern art enthusiasts.

## Culinary Delights

Odense is a foodie's paradise with a thriving culinary scene. From cozy cafes to gourmet restaurants, the city offers something for every palate. Don't miss the chance to try traditional Danish dishes, local seafood, and pastries, or explore the trendy food markets like Storms Pakhus, where you can sample a variety of international cuisines in a vibrant atmosphere. Other recommendable restaurants include Michelin star appointed Restaurant ARO, Kok & Vin, GOMA, Brasserie Bordeaux, Café Fleuri and the Italian I Pupi Siciliano.

## Shopping and Leisure

The pedestrian streets of Odense are lined with a mix of well-known brands, unique boutiques, and specialty shops, making it a great place for shopping. After a day of exploring, relax in one of the many parks or along the scenic Odense River. The city's vibrant nightlife offers bars, pubs, and live music venues, providing entertainment into the evening.



We greatly appreciate the organizers as well as  
our collaborators & contributors.

Thank you!



DANSK SELSKAB FOR KLINISK FARMAKOLOGI



Department of  
Clinical Pharmacology  
OUH  
Odense University Hospital  
Svendborg Hospital

